Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 47Head & Neck 4Gynecologic 4Genitourinary 4Lymphoid 3Thoracic 2NET 2Endocrine 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Sarcoma 727Glioblastoma 354Gliosarcoma 341Brain Neoplasms 254Central Nervous System Neoplasms 223Astrocytoma 204Osteosarcoma 202Gastrointestinal Stromal Tumors 176Dendritic Cell Sarcoma, Interdigitating 174Glioma 165Lymphoma 163Burkitt Lymphoma 162Precursor Cell Lymphoblastic Leukemia-Lymphoma 158Neoplasms 155Lymphoma, Non-Hodgkin 151Oligodendroglioma 147Recurrence 138Lymphoma, Large B-Cell, Diffuse 133Neuroblastoma 130Lymphoma, Follicular 127Breast Neoplasms 121Leukemia, Lymphocytic, Chronic, B-Cell 120Lymphoma, Mantle-Cell 119Leukemia 116Lymphoma, B-Cell, Marginal Zone 113Lymphoma, Large-Cell, Immunoblastic 112Rhabdomyosarcoma 111Hodgkin Disease 110Bone Neoplasms 109Sarcoma, Kaposi 102

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Digestive System Diseases × Sarcoma × Clear all
NCT00867113 2018-03-14

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Novartis

Phase 2 Completed
91 enrolled 11 charts
GastrointestinalSarcoma

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡